linjc16/ctgov huggingface dataset:
the Effect of Universal Salt Iodization on Thyroid Diseases

Study Overview
=================
Brief Summary
-----------------
acquire the environmental iodine status of Hangzhou acquire the iodine status of population in Hangzhou acquire the prevalence of thyroid diseases in Hangzhou explore the association between iodized salt and thyroid disease

Conditions
-----------------
Thyroid Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 6 years old; living for above 5 years at present residence. Exclusion Criteria: resident with coronary angiography (CAG) or endoscopic retrograde cholangiopancreatography (ERCP) in 6 months; resident taking amiodarone drug; resident with abnormal kidney function or serious illness

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 86 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| thyroid nodule<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| thyroid nodule | An ultrasound examination of the thyroid was performed to detect thyroid nodules, using a Sonoline Versa Pro (Siemens, Munich, Germany) with a 7.5-MHz, 70-mm linear transducer (effective length, 62 mm). | 8:00am (day 1) |
Open-label Study of TAK-875

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of treatment with TAK-875 in diabetic patients.

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: TAK-875
* Drug: TAK-875


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The participant is an outpatient. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. Exclusion Criteria: The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TAK-875 25 mg<br> | Drug: TAK-875<br> <br> |
| Experimental: TAK-875 50 mg<br> | Drug: TAK-875<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy
Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Study Overview
=================
Brief Summary
-----------------
The OPTIMISE study is a prospective, multi-center, multi-national, structured data collection initiative, first compiling data on the current treatment of post myocardial infarction patients (screening-log) and then, prospectively evaluating only those patients being prescribed Omacor as part of their standard secondary prevention treatment. The aim is to observe the Omacor cohort of patients for a period of 12 months, collecting long term observational data as clinical and patient-reported outcomes, especially, but not exclusively, recurrent non fatal Myocardial Infarction (MI), sudden death, or new Congestive Heart Failure (CHF). No predefined additional visits, medical tests, labs, procedures or interventions will be mandated. Only results from routinely performed tests, labs, procedures and/or interventions will be collected if available.

Official Title
-----------------
Omacor Plus Standard Therapies In Post MI Subjects Evaluation: The OPTIMISE Study

Conditions
-----------------
Myocardial Infarction (MI)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Male and female patients, from the screening-log, having been prescribed prior to their inclusion in the study Omega-3-fatty-acid ethyl esters (Omacor) as adjuvant treatment in secondary prevention after their myocardial infarction, in addition to standard therapy [e.g. statins, antiplatelet medicinal products, beta blockers, Angiotensine Converting Enzyme (ACE) inhibitors/Angiotensine II Receptor Blockers (ARBs), etc]. Exclusion Criteria Omega-3-fatty-acid ethyl esters (Omacor) approved contra-indication as per the labeling information in participating countries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Post Myocardial Infarction<br>One single cohort of Index post Myocardial Infarction patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Occurrences of Cardio-vascular Events | Such as: recurrent non fatal Myocardial Infarction (MI), sudden death, or new Congestive Heart Failure (CHF) | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Secondary prevention post MI
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Lung cancer is the leading cause of death in the world. Overall 5-year survival rate is fewer than 10% and the effectiveness of conventional chemotherapy is limited. The new knowledge shows the correlation between genetic alteration and effective of chemotherapy. Therefore non-surgical modalities to obtain tumor specimens for genetic alteration analysis are particularly critical in lung cancer, since many patients have advanced disease at the time of first presentation, and are therefore not eligible for radical surgery. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples obtained during diagnosis of lung cancer can be used for molecular analysis that will predict response to treatment and prognosis. In this study, we will detect specific target molecules related to the effectiveness of treatment (surgery, chemotherapy, radiotherapy) and prognosis in patients with lung cancer using EBUS-TBNA samples and its combined with xenograft technology.

Official Title
-----------------
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older. Patients with confirmed or suspected lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum will be considered for the trial. Patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for lung cancer in which a tissue diagnosis is required. Exclusion Criteria: Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy. Patients where there is a high clinical suspicion of lymphoma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| confirmed or suspected lung cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of this study is to perform gene alteration analysis using samples obtained by EBUS-TBNA in lung cancer patients. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients, undiagnosed enlarged, lymph nodes
Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Recently, many gynecologic oncologists proposed that surgeons should consider opportunistic salpingectomy to prevent ovarian cancer for all patients undergoing hysterectomy for benign disease. However, the safety and the consequences regarding ovarian function after salpingectomy have not yet to be established. Therefore, the aim of this randomized controlled study is compare the ovarian reserve via anti-Müllerian hormone (AMH) between laparoscopic hysterectomy (LH) alone and LH combined with salpingectomy.

Official Title
-----------------
Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy: a Multi-center, Randomized Controlled Trial

Conditions
-----------------
Benign Uterine Disease

Intervention / Treatment
-----------------
* Procedure: LH alone
* Procedure: LH with opportunistic salpingectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women who were planning to undergo laparoscopic hysterectomy for benign uterine diseases women aged between 19 and 52 years women with regular menstruation (defined as the duration of menstrual cycle between 21 and 45 days) women who were appropriated medical status for laparoscopic surgery Exclusion Criteria: any ovarian cysts requiring ovarian surgery any suspicious findings of malignant diseases history of prior salpingectomy or salpingo-oophorectomy pregnant or menopausal status preoperative serum anti-Müllerian hormone (AMH) < 0.30 ng/mL use of hormonal treatments in the three months before surgery any other endocrine disease (such as uncontrolled thyroid dysfunction, hyperprolactinemia, or Cushing syndrome) an inability to understand and provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 52 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: LH alone<br>LH, laparoscopic hysterectomy | Procedure: LH alone<br>* LH, laparoscopic hysterectomy<br>|
| Experimental: LH with opportunistic salpingectomy<br>LH, laparoscopic hysterectomy | Procedure: LH with opportunistic salpingectomy<br>* LH, laparoscopic hysterectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in ovarian reserve | The primary outcome measure was the change of ovarian reserve, determined by the rate of decline in AMH level from before surgery to 3-month post-surgery with the following formula : decline rate (%) = 100 × (preoperative AMH level - postoperative AMH level) ÷ preoperative AMH level. | 3 months after surgery |
Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers

Study Overview
=================
Brief Summary
-----------------
Anxiety and depression are often present in patients with chronic heart failure (CHF). This study aimed to evaluate the influence of anxiety and depression on the physical function, disability, and quality of life (QOL) in CHF. This study examined the effects of 8-week home-based exercise on these parameters, and investigated the correlations between these outcome changes.

Official Title
-----------------
Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers

Conditions
-----------------
Chronic Heart Failure (CHF), Anxiety and Depression, Quality of Life (QOL), Exercise

Intervention / Treatment
-----------------
* Other: Home-based exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of CHF for more than 6 months (NYHA Classes I-III) Medically stable for at least 3 months Exclusion Criteria: Malignancy Psychiatric disease, primary neuromusculoskeletal or respiratory diseases that affected the assessment of functional or exercise capacity Changes in medication occurred during the study period

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br> | Other: Home-based exercise<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychologic aspect | Anxiety and depression was measured by Hospital Anxiety and Depression Scale (HADS). | 8 weeks | 
| Functional capacity | Functional capacity was assessed by six-minute walk test (6MWT). | 8 weeks | 
| Disability level | Groningen Activity Restriction Scale (GARS) | 8 weeks | 
| Quality of life | Minnesota Living with Heart Failure Questionnaire (MHFQ) was used to assess quality of life. | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic heart failure (CHF); anxiety and depression; quality of life (QOL); exercise
Predicting Exacerbation of COPD With Wireless Telemonitoring

Study Overview
=================
Brief Summary
-----------------
This is an open-label single-center 6-month prospective clinical trial predicting exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep in patients admitted to the pulmonary ward of the Turku University Hospital due to acute exacerbation of COPD.

Detailed Description
-----------------
A bed sensor based on ballistocardiogram (BCG) will be used to wireless telemonitoring of respiratory rate, heart rate and sleep for six months after an acute exacerbation of COPD.

Official Title
-----------------
Open-Label Prospective Study of Predicting Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) With Wireless Telemonitoring of Respiratory Rate, Heart Rate and Sleep

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Device: telemonitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients treated due to acute exacerbation of COPD at the pulmonary wards of the Turku University Hospital Exclusion Criteria: Those sleeping with a bed partner and not having separate mattresses Patients with pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telemonitoring<br>Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep. | Device: telemonitoring<br>* To predict exacerbation of COPD with wireless telemonitoring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time window to detect acute exacerbation of COPD | Time window to detect acute exacerbation of COPD | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, telemonitoring, exacerbation
The Use of the Hem-o-lok Clip in Appendectomy: Single or Double?

Study Overview
=================
Brief Summary
-----------------
Stump safety is provided by different methods in laparoscopic appendectomy. Stapler use, binding with endoloop and nonabsorbable clip are the most common methods. Although the stapler is safe, it creates a significant cost increase. In connecting with the endoloop, the learning curve and surgical time are longer. Nonabsorbable clip application which has been used recently; Urethra was also used in appendectomy after its safety has been proven by large studies to close cystic ducts and vascular structures. Its advantages such as low cost, no need for a learning curve and shortening the surgical time have increased the frequency of use.In this prospective observational study; It will be aimed to investigate the effects of stump closure methods applied in laparoscopic appendectomy on short-term clinical results. In addition, the factors that determine the surgeon's stump closure method and cost results will be tried to be determined.

Detailed Description
-----------------
Detailed explanation will be made later if necessary.

Official Title
-----------------
Comparison of Single and Double Hem-o-log Clips in Laparoscopic Appendectomy

Conditions
-----------------
Acute Appendicitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria diagnosis of acute appendicitis Performing laparoscopic surgery Patients with an ASA score of I-II-III Exclusion Criteria: Appendectomies with the patient's refusal to participate in the study Open surgery Primary pathology without appendicitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Is it safe to close the appendix stump with a single hem-o-lok clip? | Complications of patients using single and double clips will be compared according to Clavien-Dindo scoring system. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of single and double hem-o-lok clips on cost in laparoscopic appendectomy | With the use of a single clip, surgery costs are expected to be less in dollars.Student's t-test will be used for cost analysis. | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laparoscopic appendectomy, Hem-o-lok clip, stump closure
Linkage Analysis in Interstitial Cystitis

Study Overview
=================
Brief Summary
-----------------
Urologic pelvic pain syndrome (UCPPS), variably termed painful bladder syndrome/interstitial cystitis (PBS/IC) in females and chronic prostatitis/chronic pelvic pain syndrome in men (CP/CPPS), is a chronic, debilitating clinical syndrome presenting as severe pelvic pain with extreme urinary urgency and frequency in the absence of any known cause. The etiologic mechanisms underlying UCPPS are unknown, but recurrence, risks to siblings of affected individuals, concordance among monozygotic twins, and our own preliminary studies indicate a strong genetic contribution to the cause of UCPPS. The overall goal of this proposal is use novel approaches to understand the basis of UCPPS, to identify candidate genes containing mutations that result in UCPPS and determine how the different encoded proteins of these genes interact with one another in a common biological pathway. Ultimately, understanding how mutations in at least five different genes yield the symptoms of UCPPS should lead to improved diagnosis and possible therapies.

Official Title
-----------------
Genetic Studies of Urologic Chronic Pelvic Pain Syndrome

Conditions
-----------------
Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic Pelvic Pain Syndrome, Painful Bladder Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have symptoms for at least 3 months within the preceding 6 months: Pain in the pelvic area Urinary frequency and/or Urinary urgency and/or Sexual dysfunction (erectile dysfunction) Have CP/CPPS, IC, PBS, or BFS Be willing to provide a saliva and urine sample Agree to complete several brief questionnaires Family of someone with CP/CPPS, PBS, IC or BFS Live in the USA or Canada Exclusion Criteria: Major structural/anatomical urinary tract abnormalities Underlying inborn or congenital conditions

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Men with chronic prostatitis/chronic pelvic pain syndrome | |
| 2<br>Women with painful bladder syndrome/interstitial cystitis | |
| 3<br>Children with overactive bladder | |
| 4<br>Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder | |
| 5<br>Asymptomatic healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic pelvic pain syndrome, Painful bladder syndrome, Urgency, Frequency